General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses

filing / Aug 5, 2026 / receipt

• costs of outside consultants, including their fees, stock-based compensation and related travel expenses; • the cost of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; • costs related to compliance with regulatory requirements; • facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of

filing / Aug 5, 2026 / receipt

On February 12, 2026, we announced that we implemented cost reduction actions, including reducing our workforce by approximately 30%.

filing / Aug 5, 2026 / receipt

During the three months ended March 31, 2026, we incurred approximately $0.9 million in restructuring costs, primarily related to severance costs, of which $0.7 million was paid during the first quarter of 2026, and the remainder was paid out in the second quarter of 2026.

filing / Aug 5, 2026 / receipt

We anticipate an overall decrease in research and development expenses in 2026 as compared to 2025, following the conclusion of the TSA, completion of the Phase 1b study of SER-155 in allo-HCT, and the cost reduction actions that were implemented in September 2025 and February 2026, including pausing investment in the SER-155 Phase 2 study and headcount reductions.

filing / Aug 5, 2026 / receipt

During the six months ended June 30, 2026, the Company incurred approximately $ 914 in restructuring costs, primarily related to severance costs, of which $ 718 was paid in the first quarter of 2026, and the remainder of these costs were paid out in the second quarter of 2026.

filing / Aug 5, 2026 / receipt

General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses

filing / May 5, 2026 / receipt

• costs of outside consultants, including their fees, stock-based compensation and related travel expenses; • the cost of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; • costs related to compliance with regulatory requirements; • facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of

filing / May 5, 2026 / receipt

On February 12, 2026, we announced that we implemented cost reduction actions, including reducing our workforce by approximately 30%.

filing / May 5, 2026 / receipt

During the three months ended March 31, 2026, we incurred approximately $0.9 million in restructuring costs, primarily related to severance costs, of which $0.7 million was paid as of March 31, 2026.

filing / May 5, 2026 / receipt

We anticipate an overall decrease in research and development expenses in 2026 as compared to 2025, following the conclusion of the TSA, completion of the Phase 1b study of SER-155 in allo-HSCT, and the cost reduction actions that were implemented in September 2025 and February 2026, including pausing investment in the SER-155 Phase 2 study and headcount reductions.

filing / May 5, 2026 / receipt

During the three months ended March 31, 2026, the Company incurred approximately $ 914 in restructuring costs, primarily related to severance costs, of which $ 718 has been paid as of March 31, 2026.

filing / May 5, 2026 / receipt